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ABSTRACT
The protein apoptotic protease activating factor 1
(Apaf1) is the central component of the apoptosome, a
multiprotein complex that activates procaspase-9 after
cytochrome c release from the mitochondria in the
intrinsic pathway of apoptosis. We have developed a
vital method that allows ﬂuorescence-activated cell
sorting of cells at different stages of the apoptotic
pathway and demonstrated that upon pharmacological
inhibition of Apaf1, cells recover from doxorubicin- or
hypoxia-induced early apoptosis to normal healthy cell.
Inhibiting Apaf1 not only prevents procaspase-9 activa-
tion but delays massive mitochondrial damage allowing
cell recovery.
KEYWORDS Apaf1, Apaf1 inhibitors, apoptosis,
apoptosome, autophagy, cell recovery
INTRODUCTION
Apoptosis is executed by highly regulated cellular pathways
and is crucial for the removal of cells with damaged DNA or
organelles, viral or bacterial infections as well as superﬂuous
or ectopic cells. Two major signaling pathways have been
described for apoptosis induction. The extrinsic pathway is
initiated through external stress signals that induce the
binding of plasma membrane proteins of the death receptor
family (Peter and Krammer, 2003). The intrinsic pathway can
be initiated by a number of factors including growth factor
withdrawal and genotoxic stress which, with the participation
of members of the Bcl-2 family of proteins, lead to mito-
chondrial outer membrane permeabilization (MOMP) (Bren-
ner and Mak, 2009). This is followed by cytochrome c (Cyt c)
release from mitochondria and formation of the cytosolic
multiprotein complex termed the apoptosome. Assembly of
the apoptosome triggers signaling cascades that activate the
caspase family of cysteine aspartyl proteases. These cas-
pases are essential to the initiation and execution of the
apoptotic process. Apoptosis dysregulation is at the root of a
variety of diseases. Apoptosis resistance has been causally
linked to cancer and autoimmune diseases, and conversely,
excessive apoptosis promotes pathological conditions rela-
ted to stroke, ischemia-reperfusion damage and degenera-
tive diseases (Green and Kroemer, 2005). While the
development of new anti-cancer therapies relies on inducing
apoptosis (Debatin, 2006), progress has been much slower
in the discovery of inhibitors of unwanted apoptosis. Initial
drug discovery efforts were directed towards the identiﬁca-
tion of executioner caspase-3 inhibitors (Linton, 2005). The
caspase-3 inhibitors showed promising potential in several
animal models of alcoholic liver diseases, hepatitis B and C
virus infection (Kunstle et al., 1997), myocardial infarction
and infarct size in stroke (Cheng et al., 1998; Yaoita et al.,
2000), sepsis (Hotchkiss and Karl, 2003), neuronal death
and in spinal cord injury (Springer et al., 1999). However,
caspase inhibitor-based drugs are experimenting slow
pharmacological advance due to the reported side effects
especially in terms of hepatotoxicity (Schotte et al., 1999;
Van Noorden, 2001; Hoglen et al., 2004). In addition, in the
development of apoptosis inhibitors it should be considered,
the necessity of maintaining cell functionality in order to
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provide long term survival rather than simply inhibiting death.
Some lines of evidence showed that merely executioner
caspase inhibition would not reach this objective. In a model
of Parkinson’s disease it was reported successful inhibition
of neuronal cells death upon treatment with Z-Val-Ala-Asp
(OMe)-ﬂuoromethylketone (zVAD-fmk), an irreversible cas-
pase inhibitor; however, the loss of neurite or reduction of
dopamine uptake was not improved with this treatment (von
Coelln et al., 2001).
When reviewing the apoptosis signaling pathway there
are several points susceptible of intervention to develop
unwanted cell death inhibitors. In this sense, the formation of
the apoptosome offered evidences to be considered as an
interesting target as it is downstream from the mitochondrial
events that characterize the pathway but upstream of
effector caspases (e.g., caspase-3/7) that are the executors
of cell death. The main constituent of the apoptosome is
Apaf1 a multidomain protein that activates upon binding to
Cyt c released from mitochondria after MOMP (Srinivasula
et al., 1998). Mochizuki et al. (2001) reported that an adeno-
associate virus vector-based delivery of an Apaf1 dominant
negative inhibitor was able to inhibit apoptosis-mediated
degeneration of nigrostriatal neurons in a MPTP model of
Parkinson’s disease. Gao et al. (2009), by means of the
overexpression of the speciﬁc Apaf1 inhibitory protein (AIP),
have reported that inhibition of Apaf1 in an animal model of
neonatal hypoxic-ischemic brain injury resulted in an atten-
uated brain tissue loss. In Apaf1 deﬁcient cells, Ferraro et al.
have demonstrated that such cells can turn-on readjust-
ments of metabolic pathways to survive apoptotic stimulus
while the depolarized state of mitochondria is reverted
(Ferraro et al., 2008). Small molecules that inhibit Apaf1 are
another promising approach for developing unwanted
apoptosis inhibitors. We have reported on a family of small
molecules that inhibits apoptosis by interfering with the
apoptosome activity (Malet et al., 2006; Mondragon et al.,
2008; Mondragon et al., 2009; Santamaria et al., 2009;
Orzaez et al., 2014; Sancho et al., 2014b). In particular,
SVT016426 was as efﬁcient as the caspase inhibitor zVAD-
fmk inhibiting the intrinsic apoptotic pathway. Here we show
that the apoptosis inhibition provided by the Apaf1 inhibitor
SVT016426 at the level of apoptosome contributes to
maintain functional cells, thus raising hope for the develop-
ment of future treatments of unwanted pathological apopto-
sis. Understanding the physiology of cell death has allowed
the development of mechanistic approaches for the devel-
opment of apoptosis-related drugs. However to properly face
death prevention and most importantly cell recovery from
early apoptosis stages, we have to understand not only how
cells die but also how cells recover. We report here on a
method to distinguish and to classify living cells at different
stages of apoptosis. The possibility of isolating cells at an
early apoptotic phase allowed us to identify autophagy as
the molecular mechanism that facilitates SVT016426-de-
pendent cell recovery.
RESULTS
Apaf1 inhibition provides survival to cells induced
to execute apoptosis
Direct damage to cells causes individual cell death that
depending on the number of cell loss can result on tissue or
organ failure; e.g. cardiac damage that occurs late after
chemotherapy (months or even a year or more) is one of the
major side effects of doxorubicin (Doxo) treatment, a drug
that is one of the most widely used anticancer drugs for solid
tumors (Takemura and Fujiwara, 2007). In other cases, as
stroke or tissue infarction, a hypoperfused, hypoxic, meta-
stable region, named the penumbra, is formed around the
core of necrotic cell death. The penumbra region retains
structural integrity but has a compromised functionality and
its long term recovery deﬁnes the basis for stroke and/or
tissue infarction therapy (Yuan, 2009). We asked whether
Apaf1 inhibition by SVT016426 could have application in
hypoxia and Doxo-induced cell death. Chemical inhibitors of
Apaf1, as SVT016426, inhibit the apoptosome-dependent
induction phase in different cells induced to execute apop-
tosis (Malet et al., 2006; Mondragon et al., 2008; Mondragon
et al., 2009; Orzaez et al., 2014). Then, we initially analyzed
the ability of SVT016426 to inhibit apoptosome activity in
HeLa cell extracts. Incubation of the cytosolic S100 cell
extract with dATP and Cyt c restored the apoptotic pathway
through induction of the apoptosome formation (Fearnhead,
2001); this restoration was followed using a ﬂuorogenic
substrate for caspases (Ac-DEVD-afc). SVT016426 treat-
ment inhibited Apaf1-induced activation of caspase activity
(Fig. 1A). We also analyzed target-speciﬁcity of SVT016426
in a model of Doxo-induced apoptosis in HeLa cells. For this
purpose, we considered the use of small interfering RNA
(siRNA)-based silencing of Apaf1 (Fig. 1B) and analyzed the
activity of SVT016426 in Doxo-induced cell death in the
presence or absence of Apaf1 in the cells. When HeLa cells
transfected with a control random siRNA were treated with
Doxo we obtained close to 60% of Doxo-induced cell death.
However in the presence of SVT016426 death decreased to
a 40% of the cell population (Fig. 1C). In contrast, Doxo-
induced cell death was not inhibited by SVT016426 in Apaf1
siRNA-based knockdown cells (Fig. 1C). It should be men-
tioned here that in the absence of Apaf1, Doxo induced a
caspase-independent cell death in these cells as it was
described previously (Miyazaki et al., 2001; Andreu-Fer-
nandez et al., 2013; Sancho et al., 2014a). These cell via-
bility results were well correlated with caspase-9 processing
(Fig. 1B) and measurements of caspase-3 activity (Fig. 1D)
suggesting that SVT016426 inhibitory capacity was depen-
dent on the levels of Apaf1 in the cell. These observations
imply that SVT016426-mediated inhibition of Apaf1 results in
pathway responses and cellular phenotypic effects compat-
ible with an Apaf1-selective inhibition of apoptosis. Then
SVT016426 not only inhibited caspase activity but also
inhibited cell death. The SVT016426-induced cell death
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inhibition was close to 20% of the total cell population. This
death inhibition ratio, although still modest, could be of rel-
evance ﬁnding ways to describe future apoptosis inhibition-
based therapies to devastating diseases as neurodegener-
ative diseases and to decrease secondary effects of cancer
chemotherapy.
Apaf1 inhibition permits cell recovery after hypoxia
or DNA-damage
We were interested in analyzing not only cell death inhibition
but also the possibility of SVT016426-dependent cell
recovery. As SVT016426 acts downstream mitochondria we
reasoned that only cells in the early phases of apoptosis
would be able to recover.
To test this hypothesis we designed a cellular assay to
separate populations in different apoptotic stages. We enri-
ched the early apoptotic cell population by applying soft con-
ditions of apoptosis induction. Then we developed a method
based in HeLa cells that overexpressed Cyt c-GFP cells
(HeLa-GFP) that allowed the analysis of cellular Cyt c-GFP
distribution in living cells. However, we found that due to
overexpression, in homeostatic HeLa-GFP cells a fraction of
Cyt c-GFP was located in the cytoplasm. Then, HeLa-GFP
cells were subjected to ﬂuorescence-activated cell sorting
(named thereof sorting, st) to select a speciﬁc and homoge-
neous HeLa-GFPst cell population with moderate Cyt c-GFP
expression levels andabsenceofCytc-GFP in cytosol to allow
further quantitative procedures. This HeLa-GFPst population
allowed setting up a method to analyze Cyt c release in living
cells subjected to long hypoxia conditions and to sub-lethal
Doxo treatment. Cyt c released from mitochondria upon an
apoptotic stimuli, is rapidly degraded by the proteasome
(MacFarlane et al., 2002; Rehm et al., 2003; Ferraro et al.,
2008), then Cyt c-GFP released from HeLa-GFPst mito-
chondria will produce a change in ﬂuorescence signal inten-
sity allowing cytoﬂuorimetricmeasurementswithout necessity
for cell permeabilization. This vital methodwould allow the cell
sorting procedures required for the analysis of cells at different
stages of the apoptotic pathway (see below). We initially set-
up themethodwithDoxo-induced apoptotic HeLa-GFPst cells
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Figure 1. Chemical inhibition of Apaf1 provides cell survival. (A) The IC50 of SVT016426 was analyzed using HeLa S100 cell
extract-based assay. Caspase-3-like activity on HeLa S100 extracts was measured in the presence or absence of increasing
concentrations of SVT016426. Data are presented as mean inhibition percentage of control ± SD, n = 3. Curve ﬁtting was performed
using GraphPad Prism 3.0 software. (B) Apaf1 was silenced in HeLa cells by siRNA (100 nmol/L) methodology. Immunoblotting for
Apaf1, caspase-9 and α-tubulin (loading control) was provided in cell extracts silenced using a random siRNA (Randsi) or Apaf1
siRNA (Apafsi). Cell survival (C) and caspase-3-like activity (D) were measured for control (Randsi) or Apaf1 (Apafsi) silencing in the
presence or absence of Doxo (1 µmol/L) and SVT016426 treatment (SVT; 5 µmol/L) (mean ± SD, n = 3). Cell viability was measured
by both, trypan blue and MTTassay. Asterisks represent signiﬁcant differences relative to apoptotic treatment as determined by one-
way ANOVA test with Bonferroni’s multiple comparison post-test (**P < 0.05).
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channel to detect GFP ﬂuorescence. We observed the
appearance of aGFP low-intensity peak (Fig. 2Aand2B; peak
2) upon apoptosis induction which was very signiﬁcantly
reduced by lactacystin-induced proteasome inhibition, thus
validating the set-up (Fig. 2A and 2B; peak 4) (Rehm et al.,
2003). To quantitatively analyze the progression of cells
through the cell death pathway according to the cytoﬂuori-
metric results, three independent cell populations were
deﬁned according to their GFP ﬂuorescence signal intensity
and size (Fig. 2C) upon apoptotic induction. The cell
population with an average size characteristic of the HeLa-
GFPst cell line (as assessed by forward scatter - FS+) and
high GFP ﬂuorescence was considered as healthy (H; GFP
+/FS+). Cells showing FS+ and diminishedGFP ﬂuorescence
signal were considered as early apoptotic (EA; GFP-/FS+)
and the cell population of reduced size (as assessed by for-
ward scatter - FS-) and low GFP ﬂuorescent signal was con-
sidered as late apoptotic (LA; GFP-/FS-). According to such
cell population deﬁnition, we applied sorting to obtain differ-
entially puriﬁed cell populations that were analyzed for GFP
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Figure 2. An experimental model to separate cellular populations at different stages of apoptotic cell death based on Cyt
c localization. (A) Determination of Cyt c release in HeLa-GFPst by ﬂow cytometry. HeLa-GFPst cells were induced to apoptosis with
1 µmol/L Doxo for 6 h in the presence or absence of 10 µmol/L of the proteasome inhibitor lactacystin. Samples were subjected to
cytoﬂuorometric analysis to detect Cyt c-GFP. Two peaks of different intensity can be distinguished. The high intensity peak
corresponds to healthy cells (Cyt c in the mitochondria). After an apoptotic insult a second peak of low intensity appears (Cyt
c released and degraded by the proteasome in the cytosol). Inhibition of the proteasome under an apoptotic insult recovers the high
intensity peak probing that the degradation of Cyt c in the cytoplasm is responsible of the low intensity peak. (B) HeLa-GFP cells
treated as described in (A) were submitted to cell sorting. Representative ﬂuorescence microscopy images of the different cellular
populations corresponding to peaks in (A) are shown. (C) HeLa-GFPst cells were induced to apoptosis either submitting cells to HX
for 4 days or adding 0.25 µmol/L Doxo for 24 h. Three different populations corresponding to healthy (H), early apoptotic (EA) and late
apoptotic (LA) could be identiﬁed according to the degree of Cyt c release and cellular size. Quantiﬁcation of the different populations
observed in the absence (Ctrl) or in the presence of the apoptotic insults (HX; Doxo) are shown in the right panel. (D) Endogenous Cyt
c localized to mitochondrial (m) and cytosolic (c) fractions in H and EA populations, respectively.
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signal under ﬂuorescence microscope (Fig. 2B) and for
endogenous Cyt c subcellular localization upon cell fraction-
ation (Fig. 2D) to corroborate that our measurements of Cyt c-
GFP mirrored the general behavior of endogenous Cyt c. As
expected, H cells appeared intensely stained with GFP
bearing a clear hallmark of mitochondrial network in both,
untreated population (Fig. 2B, peak 1) as well as in cells iso-
lated from the GFP+/FS+ peak upon Doxo treatment (Fig. 2B,
peak 3). In contrast, cells pooled from the GFP- peak that
appeared uponDoxo treatment were signiﬁcantly less intense
(Fig. 2B, peak 2) whereas GFP-associated ﬂuorescence
intensity of Doxo and lactacystin-treated cells was similar to
that of the healthy untreated cells (Fig. 2B, peak 4). Impor-
tantly, endogenous Cyt c was conﬁned to mitochondria in H
cell population while it was found at cytosolic fractions in EA
cell population (Fig. 2D). These results suggest that mito-
chondrial released Cyt c is susceptible of a proteasome-de-
pendent degradation that can be partially inhibited by
proteasome inhibitors. To further validate our experimental
system of puriﬁcation of cell populations at different stages in
the apoptotic pathway, we performed measurements of cas-
pase-3/7 activity. As expected, no caspase-3/7 activity was
detected in H or EA cells (results not shown).
Next, we addressed the question if apoptosis induced by
different apoptotic insults can be not only prevented by
SVT016426-dependent Apaf1 inhibition but also whether or
not cells can be recovered from such insults. Experimental
cellular models of hypoxia and Doxo-induced apoptosis were
then evaluated. HeLa-GFPst cells were incubated in
hypoxia/hypercapnea (HX) conditions (1% O2, 18% CO2)
conditions for 4 days or treated with 0.25 µmol/L Doxo for
24 h and submitted to sorting in order to obtain clean pools of
H, EA and LA cells. The cross-contamination among the
different pools was thoroughly controlled and was kept as
low as less than 1% (0.6%–0.7% in most cases, data not
shown). The three different cell pools were then plated on
dishes and maintained in HX conditions for 6 additional days
or treated further with 0.5 µmol/L Doxo for 24 h in the
presence or absence of 5 µmol/L SVT016426 (scheme in
Fig. 3A and 3B upper panels). The cytoﬂuorimetric mea-
surements revealed that only 30% of the initial H cells in
prolonged HX conditions and 50% of the Doxo-treated H
cells remained without entering the cell death pathway.
However, in the presence of the Apaf1 inhibitor SVT016426
the number of unaffected H cells increased to 49% ± 2% and
to 56% ± 5% for the HX and Doxo treated cells, respectively.
This increase was correlated with a 1.6-fold reduction of the
number of LA cells (from 38% ± 4% to 23% ± 4%) in the case
of the HX population, thus conﬁrming the protective effect
that chemical Apaf1 inhibitors exert on cells previous to the
apoptotic insult. The EA pool subjected to the HX conditions
by the 6 additional days or exposed to Doxo progressed
through the cell death pathway as assessed by the presence
of 48% ± 7% or 7% ± 1% of LA cells, respectively (Fig. 3A
and 3B lower panels; Fig. S1B). In HX conditions, treatment
with SVT016426 decreased the number of the LA cells by a
3.3-fold to 15% ± 2% concomitant with a markedly increase
in the EA population (37% ± 4% to 58% ± 4% in control and
SVT016426 treated, respectively). Moreover, we observed
that the presence of H cells from a pool of pure EA cells was
substantially increased in those EA cells treated with
SVT016426 (from 15% ± 2% to 27% ± 1% on the EA cell
population under HX and from 23% ± 5% to 50% ± 6% in the
EA cell population treated with Doxo) (Fig. 3A and 3B lower
panel white bars; Fig. S1A). These results suggest that cells
which were plated as a pure EA population triggered an
SVT016426-dependent recovery program. Then, inhibition
of Apaf1 not only prevents cells entering the apoptotic pro-
gram but helps cells to recover from early apoptotic stages.
SVT016426 treated cells are able to initiate a normal cell
division program as previously demonstrated in colony for-
mation assays (Orzaez et al., 2014). As expected, the LA
population did not undergo any changes (data not shown).
Autophagy is implicated in SVT016426 cell recovery
Autophagy is a catabolic cytoprotective mechanism that
constitutes a cellular defense against stress induced by
starvation (Madeo et al., 2010). It is characterized by the
formation of double-membrane vesicles named autophago-
somes that engulf cytoplasmic organelles and proteins. The
autophagosomes fuse with lysosomes and their luminal
content is degraded. Beclin-1 is a protein characterized as
essential for the initiation of autophagy. In fact, it has been
demonstrated that is the activation of a Beclin-1 dependent
autophagy pathway that permits glycolytic-dependent ATP
generation allowing recovery from death-stimulus of apop-
tosome-deﬁcient proneural cells (Ferraro et al., 2008). We
were interested in analyzing the role of autophagy in the
SVT016426-dependent cell recovery from an early apoptotic
to a healthy state. Thus, we analyzed the protein levels of
Beclin-1, p62 and the lipidated form of the microtubule-as-
sociated protein 1A/1B-light chain 3 alpha type I (LC3-I)
(Kabeya et al., 2000; Kabeya et al., 2004) as hallmarks of
induced autophagy. Indeed, we observed an overexpression
of Beclin-1, a lipidation of the LC3-I (LC3-II) and, a moderate
decrease of p62 substrate, in SVT016426-treated when
compared to unprotected HeLa cells under HX conditions
(Fig. 4A), thus suggesting an increased rate of autophagy
(Boya et al., 2005; Pattingre et al., 2005). The presence of
autophagosome structures was also observed by transmis-
sion electron microscopy (TEM, Fig. 4B and 4C). Similar
observations were derived from SVT016426-treated cells
when Doxo was used as apoptotic insult (Fig. 5A and 5B).
The SVT016426-dependent autophagy induction correlated
with an increment in the ATP levels in SVT016426-treated
HeLa cells under HX conditions (Fig. 4D) or treated with
Doxo (Fig. 5C) when compared with cells not receiving the
SVT016426 treatment. Finally, to conﬁrm that cell recovery
was mediated by the activation of the autophagy program we
silenced Beclin-1 in the Doxo model and cell survival was
analyzed. As expected, recovery by SVT016426 is not
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observed when Beclin-1 is knocked-down thus reinforcing
the hypothesis that autophagy could be implicated in cell
recovery (Fig. 5D).
DISCUSSION
Here we have described an Apaf1-dependent cell program
that permits cells to recover from intrinsic apoptotic insults.
The use of selective chemical Apaf1 inhibitors (SVT016426
is a representative member) as chemical biology probes
highlighted Apaf1 as a principal regulator not only in cell
death but also in cell recovery pathways. As shown here,
chemical inhibition of Apaf1 is necessary to allow intrinsic
apoptosis-injured cells to have access to survival events that
implies the participation of autophagy. The pro-survival
adaptive function of autophagy acquires then relevance in
this context. Our results suggest that cells at early stages of
execution of the apoptotic program, even after Cyt c loss,
can be recovered to cells with hallmarks of normal (healthy)
cells. The cells readapt metabolic conditions and activate
autophagy to sustain ATP production. It has been previously
shown that Apaf1 genetically deprived proneural cells of
embryonic origin can recover from apoptosis when glycolysis
is active and the apoptotic stimulus is removed (Ferraro
et al., 2008).
Our study combines the use of homogeneous well
deﬁned cell populations at different stages of apoptosis with
small molecules that allowed the characterization of speciﬁc
recovery programs. In cells of mammalian origin it has
been long observed that the responsiveness to physiolog-
ical stimuli is not uniform. In particular when a clonal cell
population is induced to commit apoptosis some cells die
while others survive. Among cells that survive one can
probably ﬁnd cells at different stages of apoptosis as it has
been reported when extrinsic apoptosis was induced (Al-
beck et al., 2008). In this study we have validated a ﬂow
cytometry-based method to distinguish and to split the dif-
ferent cell populations originated when an original cell
population was subjected to intrinsic apoptosis stimuli. The
efﬁcient characterization of three (healthy, early- and late-
apoptosis) populations has permitted to unambiguously
determine that the Apaf1 inhibitor not only prevents cell
death but helps cells to recover from apoptosis. Overall,
SVT016426 provides a powerful tool for characterizing the
role of Apaf1. Such inhibitors were originally identiﬁed while

























































Figure 3. Apaf1 chemical inhibition allows cell recovery after the onset of apoptosis. (A) HeLa-GFPst cells were sorted after
4 days of HX into H, EA and LA (not shown) populations. H and EA cells were reseeded and resubmitted to HX for 6 additional days in
the presence or absence of 5 µmol/L SVT016426. The evolution of the different populations at the end of the experiment was
quantiﬁed by ﬂow cytometry. (B) HeLa-GFPst cells were induced to apoptosis by adding 0.25 µmol/L Doxo. As in (A), cells were
sorted into H, EA and LA (not shown) populations. H and EA cells were reseeded and treated with 0.5 µmol/L Doxo for an additional
period of 24 h in the presence or absence of 5 µmol/L SVT016426. The evolution of the different populations at the end of the
experiment was quantiﬁed by ﬂow cytometry. Data represent mean ± SD of three independent experiments.
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of procaspase-9 when analyzed in an in vitro reconstituted
apoptosome (Malet et al., 2006). It is now well established
that the Apaf1 inhibitors provide cytoprotective effect to cells
subjected to apoptosis stimulus in different cellular models
(Malet et al., 2006; Mondragon et al., 2008; Santamaria et al.,
2009; Orzaez et al., 2014; Sancho et al., 2014b). Further-
more, the Apaf1 inhibitor has been used to conﬁrm the effect
of caspase-3 inhibition on GluR1 synaptic distribution in a
mouse model of Alzheimer’s disease (D’Amelio et al., 2011).
The discovery of candidate drugs that attenuate the
effects of unwanted excessive apoptosis will beneﬁt from the
knowledge of how after an apoptotic stimulus, cells are able
to recover and the molecular mechanisms that use cells to
this end. Recent data (Ferraro et al., 2008) suggest that such
cellular recovery should use still undiscovered pathways that
link intrinsic apoptosis and metabolism networks. Albeck
et al. (Albeck et al., 2008) using single-cell analysis
approaches demonstrated that upon deﬁned metabolic
conditions, cells induced to extrinsic apoptosis can recover.
In contrast, the links between the intrinsic apoptosis pathway
and cellular pathways that could permit cell recovery still
present more questions than answers. Nevertheless current
knowledge suggests that the apoptotic machinery should
interact functionally with key decision-making components of
cellular metabolism (Colell et al., 2007; Ferraro et al., 2008)
cell growth and cell division. These components would pro-
vide crosstalks between the intricate cellular pathways that
deﬁne a particular cellular fate.
Early studies pointed to inhibitors of caspases as the
most attractive molecules to develop anti-apoptotic drugs;
however, chemical inhibition or knocking-out caspases is
only able to prevent apoptosis but not cell death (Boya et al.,
2005). In these conditions cells die by different processes.
Using our system to split cells at different stages of the
apoptotic program, we demonstrated that inhibition of Apaf1
enhanced apparition of healthy cells within the early apop-
totic population. Similar behavior has been reported in
C. elegans. Cells that undergo morphological changes
accompanying CED-3 activation could recover completely
when subjected to weak pro-apoptotic signals if they were
not engulfed by phagocytic cells (Hoeppner et al., 2001;















































Figure 4. Autophagy is implicated in cell recovery upon Apaf1 inhibition. (A) HeLa cells were treated as in Fig. 3A and
expression changes of proteins implicated in autophagy, namely Beclin-1, p62 and LC3-I and -II (the lipidated form of LC3-I), were
evaluated by Western blot. Gapdh was used as loading control. (B) Cellular morphology of HX-treated HeLa cells was analyzed by
transmission electron microscopy (TEM). Representative images of HX-control and HX-SVT016426 treated cells are shown (Black
arrows indicate the presence of autophagosomes). Scale bar equal to 1 µm. (C) Quantiﬁcation of the number of autophagosomes per
ﬁeld was performed analyzing 40 randomly selected ﬁelds per image from two independent experiments. (D) The ATP content per cell
in the presence or absence of 5 µmol/L SVT016426 was measured. Results shown are the mean of three independent experiments.
Statistical signiﬁcance was assessed by means of two-tailed Student’s t-test (*P < 0.05; ***P < 0.001).
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A cell full recovery mechanism must be a complex pro-
cess that has to overcome irreversible caspase-dependent
cleavage of substrates through restraining caspase-3 cat-
alytic activity. This function is played by inhibitor of apoptosis
proteins (IAPs) and proteasome-dependent caspase degra-
dation (Albeck et al., 2008). Our data identify Apaf1 as a
molecule that should be included in light of its role, when
chemically inhibited, as a molecule participating in the
process.
Several evidences have demonstrated that differentiated
cells can recover after MOMP (Martinou et al., 1999; Desh-
mukh et al., 2000; Tang et al., 2009) and our study identiﬁes
Apaf1 and autophagy induction as part of the molecular
mechanism of the recovery process, in particular in cells
affected by hypoxic or sublethal doses of intrinsic apoptosis
inducers. However, which is the mechanism and the com-
ponents of the machinery providing cell recovery and whe-
ther and how they regulate apoptosis remain to be
elucidated.
MATERIALS AND METHODS
Cell culture, reagents and antibodies
HeLa and HeLa-GFP cells were maintained in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) supplemented with 10% foetal bovine
serum (FBS). Media and supplements for cell culture were pur-
chased from Gibco-Invitrogen. Doxorrubicin (Doxo) was obtained
from Sigma-Aldrich. Anti LC3 and anti caspase-9 antibodies were
purchased from Cell Signaling. Anti Beclin-1 and anti Apaf1 anti-
bodies were purchased from BD Transduction Laboratories, p62
antibody from Enzo Life Sciences and anti α-tubulin from Sigma-
Aldrich.
Cell-free caspase activation assay
S100 cytosolic extract from HeLa was obtained as previously
described (Dignam et al., 1983; Malet et al., 2006). Extract (0.1 mg/mL)
was incubated with different concentrations of SVT016426 (0, 1, 5,



















































































Figure 5. Autophagy is implicated in cell recovery upon Apaf1 inhibition. (A) Representative TEM images of HeLa cells treated
with 0.25 µmol/L Doxo for 24 h and maintained for additional 24 h with 0.5 µmol/L Doxo in the presence or absence of 5 µmol/L
SVT016426. Black arrows indicate the presence of autophagosomes. Scale bar equal to 1 µm. (B) Quantiﬁcation of the number of
autophagosomes per ﬁeld was performed analyzing 40 randomly selected ﬁelds per image from two independent experiments.
(C) Measurement of ATP content per cell in HeLa cells treated as described in (A) in the presence or absence of 5 µmol/L
SVT016426. Statistical signiﬁcance was assessed by means of two-tailed Student’s t-test (*P < 0.05; ***P < 0.001). (D) Cell survival
was measured by MTT for control (Randsi) or Beclin (Beclinsi) silencing in the presence or absence of Doxo (1 µmol/L) and
SVT016426 treatment (SVT; 5 µmol/L) (mean ± SD, n = 3). Asterisks represent signiﬁcant differences relative to apoptotic treatment
as determined by one-way ANOVA test with Bonferroni’s multiple comparison post-test (**P < 0.05). Immunoblotting for Beclin-1 and
α-tubulin (loading control) was provided in cell extracts silenced using a random siRNA (Randsi) or Beclin siRNA (Beclinsi). Asterisk
marks for unspeciﬁc bands recognized by the antibody.
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KCl, 1.5 mmol/L MgCl2, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L
DTT, 0.1 mmol/L PMSF) plus dATP (10 mmol/L) and Cyt c (10 µmol/L)
for 40 min at 30°C. Ac-DEVD-afc substrate (20 μmol/L; Enzo Life
Sciences) was used to measure caspase-3-like activity using a
Victor 2 spectroﬂuorimeter.
Cell-based caspase activation assay
HeLa cells were seeded in 6-well plate at a cellular density of 1 × 105
cells/mL. Then, LipofectamineTM 2000 (Invitrogen) was used
according to the manufacturer’s instructions to transfect cells with a
control random siRNA (Randsi; 100 nmol/L) and Apaf1 siRNA
(Apafsi; 100 nmol/L) from Cell Signaling. 24 h later, cells were pre-
treated with SVT016426 (5 µmol/L) for 1 h, then Doxo (1 µmol/L)
was added. After 24 h cells were harvested and cytosolic extracts
were obtained as described previously. Total protein (50 µg) was
mixed with assay buffer containing 20 μmol/L Ac-DEVD-afc sub-
strate. Activity was measured using a Victor 2 spectroﬂuorimeter.
Trypan blue cell viability assay
HeLa cells seeded and treated as described before, were detached
and 0.5% trypan blue dye added in solution. Live cells possess intact
cell membranes that exclude the dye, whereas dead cells do not.
Unstained (viable) and stained (non-viable) cells were counted
separately in a hemacytometer and total number of viable cells in the
population was calculated.
MTT assay
Mitochondrial activity was measured using a MTTcolorimetric assay.
HeLa cells were grown in 24-well plates at a cell density of 1.0 × 105
cells/well. After 24 h, cells were transfected with a control random
siRNA (Randsi; 100 nmol/L) and Beclin-1 siRNA (Beclinsi; 100 nmol/L)
from Cell Signaling. 24 h later, cells were treated with SVT016426
(5 µmol/L) and Doxo (1 µmol/L) for 30 h. Four hours before the end
of the treatment 20 µL/well of MTT (5 mg/mL in PBS) was added to
each well and the plates were incubated for a further 4 h at 37°C.
Finally, the medium was removed and the precipitated formazan
crystals were dissolved in optical grade DMSO. The plates were
read at 570 nm on a Victor 2 spectroﬂuorimeter.
Hypoxia treatment and cell sorting
HeLa-GFP cells were seeded at 7.5 × 105 cells/mL on a 150 mm
sterile dish, allowed to set for 24 h. Cultures were submitted to HX
for 4 days in Thermo Electron Corp. incubator. Populations were
sorted in a Beckman Coulter MOFLO High Speed Cell Sorter,
according to the size and GFP signal intensity as explained in the
main text. After sorting, cells were seeded in 6-well plates at a cell
density of 1.5 × 105 cells/mL, treated or not with 5 μmol/L
SVT016426 and placed for additional 6 days in HX. Cell population
analysis was performed using a Beckman Coulter cytoﬂuorometer.
Doxorubicin treatment and cell sorting
HeLa-GFP cells were seeded at 7.5 × 105 cells/mL on a 150 mm
sterile dish, allowed to set for 24 h and treated with 0.25 μmol/L
Doxo for additional 24 h. Populations were sorted as described
above and treated for 24 h with 0.5 μmol/L Doxo. Cell population
analysis was performed in a Beckman Coulter cytoﬂuorometer.
Transmission electron microscopy
HeLa cells were seeded at 3 × 104 cells per chamber in a Lab-Tek
chamber slides of 4 wells (Nalge Nunc International) and treated as
indicated in each case. Then, the cells were ﬁxed for 1 h in 3.5%
glutaraldehyde at 37°C and postﬁxed for 1 h in 2% OsO4 at room
temperature. Cellular staining was performed at 4°C for 2 h in 2%
uranyl acetate in the dark. Finally, cells were rinsed in sodium
phosphate buffer (0.1 mol/L, pH 7.2), dehydrated in ethanol, and
inﬁltrated overnight in Araldite (Durcupan, Fluka). Following poly-
merization, embedded cultures were detached from the chamber
slide and glued to Araldite blocks. Serial semi-thin (1.5 μm) sections
were cut with an Ultracut UC-6 (Leica), mounted onto slides and
stained with 1% toluidine blue. Selected semi-thin sections were
glued (Super Glue, Loctite) to araldite blocks and detached from the
glass slide by repeated freezing (in liquid nitrogen) and thawing.
Ultrathin (0.07 μm) sections were prepared with the Ultracut and
stained with lead citrate. Finally, photomicrographs were obtained
under a transmission electron microscope (FEI Tecnai Spirit G2)
using a digital camera (Morada, Soft Imaging System, Olympus).
ATP measurements
HeLa cells were seeded at a density of 5 × 104 cells/mL and treated
as indicated. ATP measurement was performed in duplicate
employing ATPLite kit (Perkin Elmer) according to manufacturer’s
instructions. The ATP content was normalized per number of cells.
Statistical analysis
Data were analysed using GraphPad software and statistical sig-
niﬁcance was assessed by means of two-tailed Student’s t-test
(*P < 0.05). All data were expressed as the mean ± SD.
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AIP, Apaf1 inhibitory protein; Apaf-1, apoptotic protease-activating
factor 1; Cyt c, cytochrome c; Cyt c-GFP, ﬂuorescent GFP-labelled
Cyt c; dATP, deoxyadenosine triphosphate; Doxo, doxorubicin;
HeLa-GFP, human cervix adenocarcinoma (HeLa) cells stably
expressing Cyt c-GFP; LC3-I, microtubule-associated protein 1A/
1B-light chain 3 alpha type I; LC3-II, microtubule-associated protein
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membrane permeabilization; TEM, transmission electron
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